Literature DB >> 25427682

Significance of serum Zn-α2-glycoprotein for the regulation of blood pressure.

Souichi Kurita1, Keisuke Takeuchi1, Yoshimi Hayashi2, Hisao Ueyama1, Dimitar P Zankov1, Xiaoling Pang1, Takanobu Otsuka2, Iwao Ohkubo3, Osamu Ogikubo4, Hisakazu Ogita1.   

Abstract

Zn-α2-glycoprotein (ZAG) (molecular weight=41 kDa) is one component in the α2 fraction of human plasma, and is reported to be associated with several diseases, such as cancers and metabolic syndromes. ZAG is also considered to be an important modulator of lipid metabolism. However, little is known about the correlation of serum ZAG levels with indicators of metabolic syndrome. Serum ZAG concentrations analyzed by enzyme-linked immunoassay were positively correlated with systolic and diastolic blood pressure in 326 subjects (236 males and 90 females) aged 17-79 years who had an annual health examination. By luciferase reporter and electrophoretic mobility shift assays, the core promoter region to regulate the ZAG gene expression was found to exist between -110 and -101. The transcription factor Sp1 interacted with this region, and Sp1 knockdown experiments showed that Sp1 critically regulated ZAG expression. Furthermore, ZAG increased the active form of RhoA, which was determined by pull-down assay. Increased serum ZAG concentrations induced, at least partly, by Sp1 may cause an increase in vascular tone through the activation of RhoA and contribute to elevated blood pressure.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25427682     DOI: 10.1038/hr.2014.165

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  37 in total

1.  Identification of serum proteins involved in pancreatic cancer cachexia.

Authors:  Klaus Felix; Frederik Fakelman; Daniel Hartmann; Nathalia A Giese; Matthias M Gaida; Martina Schnölzer; Thomas Flad; Markus W Büchler; Jens Werner
Journal:  Life Sci       Date:  2010-11-19       Impact factor: 5.037

2.  Downregulation of fetuin-B and zinc-α2-glycoprotein is linked to impaired fatty acid metabolism in liver cells.

Authors:  Jung-Won Choi; Hao Liu; Rajib Mukherjee; Jong Won Yun
Journal:  Cell Physiol Biochem       Date:  2012-06-22

3.  Dephosphorylation of Sp1 at Ser-59 by protein phosphatase 2A (PP2A) is required for induction of CYP1A1 transcription after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin or omeprazole.

Authors:  Shuji Shimoyama; Shuya Kasai; Brigitte Kahn-Perlès; Hideaki Kikuchi
Journal:  Biochim Biophys Acta       Date:  2013-12-29

4.  Zinc-alpha2-glycoprotein expression as a marker of differentiation in human oral tumors.

Authors:  M M Brysk; G Lei; K Adler-Storthz; Z Chen; H Brysk; S K Tyring; I Arany
Journal:  Cancer Lett       Date:  1999-03-22       Impact factor: 8.679

5.  Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes.

Authors:  Yi Bao; Chen Bing; Leif Hunter; John R Jenkins; Martin Wabitsch; Paul Trayhurn
Journal:  FEBS Lett       Date:  2005-01-03       Impact factor: 4.124

6.  Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients.

Authors:  K Hirai; H J Hussey; M D Barber; S A Price; M J Tisdale
Journal:  Cancer Res       Date:  1998-06-01       Impact factor: 12.701

7.  Rho and anillin-dependent control of mDia2 localization and function in cytokinesis.

Authors:  Sadanori Watanabe; Katsuya Okawa; Takashi Miki; Satoko Sakamoto; Tomoko Morinaga; Kohei Segawa; Takatoshi Arakawa; Makoto Kinoshita; Toshimasa Ishizaki; Shuh Narumiya
Journal:  Mol Biol Cell       Date:  2010-07-21       Impact factor: 4.138

8.  EphA4-mediated Rho activation via Vsm-RhoGEF expressed specifically in vascular smooth muscle cells.

Authors:  Hisakazu Ogita; Satoshi Kunimoto; Yuji Kamioka; Hirofumi Sawa; Michitaka Masuda; Naoki Mochizuki
Journal:  Circ Res       Date:  2003-05-29       Impact factor: 17.367

9.  The adipokine zinc-alpha2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity.

Authors:  T Mracek; Q Ding; T Tzanavari; K Kos; J Pinkney; J Wilding; P Trayhurn; C Bing
Journal:  Clin Endocrinol (Oxf)       Date:  2009-06-22       Impact factor: 3.478

10.  Role of beta3-adrenergic receptors in the action of a tumour lipid mobilizing factor.

Authors:  S T Russell; K Hirai; M J Tisdale
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

View more
  5 in total

1.  Development of a prediction model for mortality and cardiovascular outcomes in older adults taking into account AZGP1.

Authors:  Elke Schaeffner; Roland Schmitt; Dörte Huscher; Natalie Ebert; Inga Soerensen-Zender; Nina Mielke
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

2.  Rutin Attenuates Hepatotoxicity in High-Cholesterol-Diet-Fed Rats.

Authors:  Shakir D AlSharari; Salim S Al-Rejaie; Hatem M Abuohashish; Mohamed M Ahmed; Mohamed M Hafez
Journal:  Oxid Med Cell Longev       Date:  2016-04-27       Impact factor: 6.543

3.  Association of metabolic syndrome components with circulating levels of cytokine clusters in young women.

Authors:  Xingrong Tan; Wenjing Hu; Shan Yang; Han Dai; Shangcheng Xu; Gangyi Yang; Ling Li; Shiguo Tang; Yi Wang
Journal:  Endocr Connect       Date:  2021-01       Impact factor: 3.335

4.  Assessment of Zinc- alpha2 glycoprotein (ZAG) and Lipase Maturation Factor 1 (LMF1) concentration in children with chronic kidney disease.

Authors:  D Roszkowska-Bjanid; K Dyga; E Świętochowska; O Bjanid; M Szczepańska
Journal:  Physiol Res       Date:  2021-06-01       Impact factor: 1.881

5.  Low Serum ZAG Levels Correlate With Determinants of the Metabolic Syndrome in Chinese Subjects.

Authors:  Linjie Wang; Meijuan Liu; Dongping Ning; Huijuan Zhu; Guangliang Shan; Dingming Wang; Bo Ping; Yangwen Yu; Hongbo Yang; Kemin Yan; Hui Pan; Fengying Gong
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-24       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.